This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (37)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Cardiovascular System  • Prognosis/ Outcomes  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

Results of the Randomized Perindopril and Remodeling in Elderly With Acute Myocardial Infarction (PREAMI) Study

The PREAMI Investigators*

Arch Intern Med. 2006;166:659-666.

Background  Angiotensin-converting enzyme inhibitors reduce mortality and remodeling after myocardial infarction in patients with left ventricular dysfunction.

Methods  Perindopril and Remodeling in Elderly With Acute Myocardial Infarction (PREAMI), a double-blind, randomized, parallel-group, multicenter, placebo-controlled study, determined whether similar benefits occur in elderly postinfarction patients with preserved left ventricular function. A total of 1252 patients 65 years or older with a left ventricular ejection fraction of 40% or higher and recent acute myocardial infarction were randomized to receive perindopril erbumine or placebo (8 mg/d) for 12 months. The combined primary end point was death, hospitalization for heart failure, or left ventricular remodeling. Secondary end points included cardiovascular death, hospitalization for reinfarction or angina, and revascularization.

Results  The primary end point occurred in 181 patients (35%) taking perindopril and 290 patients (57%) taking placebo, with a significant absolute risk reduction of 0.22 (95% confidence interval, 0.16 to 0.28; P<.001). A total of 126 patients (28%) and 226 patients (51%) in the perindopril and placebo groups, respectively, experienced remodeling. The mean increase in left ventricle end-diastolic volume was 0.7 mL with perindopril compared with 4.0 mL with placebo (P<.001). In the perindopril group, 40 deaths (6%) and 22 hospitalizations (4%) for heart failure occurred, whereas 37 deaths (6%) and 30 hospitalizations (5%) occurred in the placebo group. Treatment did not affect death, whereas the hospitalization rate for heart failure was slightly reduced (absolute risk reduction, 0.01; 95% confidence interval, –0.01 to 0.02). No treatment effect on other secondary end points was detected.

Conclusion  We found that 1-year treatment with 8 mg/d of perindopril reduces progressive left ventricular remodeling that can occur even in the presence of small infarct size, but it was not associated with better clinical outcomes.

*Author: The author for the PREAMI Investigators is Roberto Ferrari, MD, PhD.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

It Is Time to Stop Comparing Blood Pressure–Lowering Drugs With Placebo
Flávio Danni Fuchs
Arch Intern Med. 2006;166(16):1786.
EXTRACT | FULL TEXT  

It Is Time to Stop Comparing Blood Pressure–Lowering Drugs With Placebo—Reply
Roberto Ferrari and for the PREAMI Investigators
Arch Intern Med. 2006;166(16):1786-1787.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effects of perindopril on cardiac remodelling and prognostic value of pre-discharge quantitative echocardiographic parameters in elderly patients after acute myocardial infarction: the PREAMI echo sub-study
Nicolosi et al.
Eur Heart J 2009;30:1656-1665.
ABSTRACT | FULL TEXT  

Post-infarct remodelling: contribution of wound healing and inflammation
Frantz et al.
Cardiovasc Res 2009;81:474-481.
ABSTRACT | FULL TEXT  

Benefits of perindopril all along the cardiovascular continuum: the level of evidence
Fox
Eur Heart J Suppl 2008;10:G4-G12.
ABSTRACT | FULL TEXT  

Treatment with angiotensin-converting enzyme inhibitors: insight into perindopril cardiovascular protection
Ferrari
Eur Heart J Suppl 2008;10:G13-G20.
ABSTRACT | FULL TEXT  

The effect of ageing on cardiac remodelling and hospitalization for heart failure after an inaugural anterior myocardial infarction
Ennezat et al.
Eur Heart J 2008;29:1992-1999.
ABSTRACT | FULL TEXT  

How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology
Paulus et al.
Eur Heart J 2007;28:2539-2550.
ABSTRACT | FULL TEXT  

Introduction
Tendera
Eur Heart J Suppl 2007;9:E1-E1.
FULL TEXT  

Angiotensin-converting enzyme inhibition: a landmark advance in treatment for cardiovascular diseases
Borer
Eur Heart J Suppl 2007;9:E2-E9.
ABSTRACT | FULL TEXT  

Contribution of perindopril to cardiology: 20 years of success
Fox
Eur Heart J Suppl 2007;9:E10-E19.
ABSTRACT | FULL TEXT  

The perindopril in elderly people with chronic heart failure (PEP-CHF) study
Cleland et al.
Eur Heart J 2006;27:2338-2345.
ABSTRACT | FULL TEXT  

It is time to stop comparing blood pressure-lowering drugs with placebo.
Fuchs
Arch Intern Med 2006;166:1786-1786.
FULL TEXT  

It Is Time to Stop Comparing Blood Pressure-Lowering Drugs With Placebo--Reply
Ferrari and for the PREAMI Investigators
Arch Intern Med 2006;166:1786-1787.
FULL TEXT